Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.936 |
High Similarity |
NPD3027 |
Phase 3 |
0.8992 |
High Similarity |
NPD1612 |
Clinical (unspecified phase) |
0.8992 |
High Similarity |
NPD1613 |
Approved |
0.8682 |
High Similarity |
NPD1529 |
Clinical (unspecified phase) |
0.8605 |
High Similarity |
NPD1530 |
Clinical (unspecified phase) |
0.8583 |
High Similarity |
NPD2982 |
Phase 2 |
0.8583 |
High Similarity |
NPD2983 |
Phase 2 |
0.8504 |
High Similarity |
NPD2981 |
Phase 2 |
0.8462 |
Intermediate Similarity |
NPD3018 |
Phase 2 |
0.8293 |
Intermediate Similarity |
NPD5283 |
Phase 1 |
0.8258 |
Intermediate Similarity |
NPD4908 |
Phase 1 |
0.8254 |
Intermediate Similarity |
NPD1548 |
Phase 1 |
0.8182 |
Intermediate Similarity |
NPD2684 |
Approved |
0.814 |
Intermediate Similarity |
NPD1610 |
Phase 2 |
0.8134 |
Intermediate Similarity |
NPD4907 |
Clinical (unspecified phase) |
0.813 |
Intermediate Similarity |
NPD228 |
Approved |
0.8065 |
Intermediate Similarity |
NPD7843 |
Approved |
0.8027 |
Intermediate Similarity |
NPD1934 |
Approved |
0.8016 |
Intermediate Similarity |
NPD7157 |
Approved |
0.8 |
Intermediate Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.7951 |
Intermediate Similarity |
NPD290 |
Approved |
0.7891 |
Intermediate Similarity |
NPD4675 |
Approved |
0.7891 |
Intermediate Similarity |
NPD4678 |
Approved |
0.7883 |
Intermediate Similarity |
NPD1558 |
Phase 1 |
0.7879 |
Intermediate Similarity |
NPD4379 |
Clinical (unspecified phase) |
0.7877 |
Intermediate Similarity |
NPD1653 |
Approved |
0.7867 |
Intermediate Similarity |
NPD3882 |
Suspended |
0.7863 |
Intermediate Similarity |
NPD3705 |
Approved |
0.7863 |
Intermediate Similarity |
NPD1091 |
Approved |
0.7852 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.7852 |
Intermediate Similarity |
NPD2801 |
Approved |
0.7842 |
Intermediate Similarity |
NPD4538 |
Approved |
0.7842 |
Intermediate Similarity |
NPD4537 |
Clinical (unspecified phase) |
0.7842 |
Intermediate Similarity |
NPD4536 |
Approved |
0.7833 |
Intermediate Similarity |
NPD291 |
Approved |
0.7832 |
Intermediate Similarity |
NPD5307 |
Clinical (unspecified phase) |
0.7817 |
Intermediate Similarity |
NPD4236 |
Phase 3 |
0.7817 |
Intermediate Similarity |
NPD4162 |
Approved |
0.7817 |
Intermediate Similarity |
NPD5698 |
Clinical (unspecified phase) |
0.7817 |
Intermediate Similarity |
NPD4237 |
Approved |
0.7801 |
Intermediate Similarity |
NPD3540 |
Phase 1 |
0.78 |
Intermediate Similarity |
NPD6374 |
Clinical (unspecified phase) |
0.78 |
Intermediate Similarity |
NPD3817 |
Phase 2 |
0.7794 |
Intermediate Similarity |
NPD4625 |
Phase 3 |
0.7778 |
Intermediate Similarity |
NPD7199 |
Phase 2 |
0.7778 |
Intermediate Similarity |
NPD2861 |
Phase 2 |
0.7769 |
Intermediate Similarity |
NPD1357 |
Approved |
0.7752 |
Intermediate Similarity |
NPD5536 |
Phase 2 |
0.7744 |
Intermediate Similarity |
NPD4749 |
Approved |
0.7742 |
Intermediate Similarity |
NPD6166 |
Phase 2 |
0.7742 |
Intermediate Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.7742 |
Intermediate Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.7737 |
Intermediate Similarity |
NPD6410 |
Clinical (unspecified phase) |
0.773 |
Intermediate Similarity |
NPD3539 |
Phase 1 |
0.7721 |
Intermediate Similarity |
NPD5752 |
Clinical (unspecified phase) |
0.771 |
Intermediate Similarity |
NPD6516 |
Phase 2 |
0.771 |
Intermediate Similarity |
NPD5846 |
Approved |
0.7703 |
Intermediate Similarity |
NPD6055 |
Clinical (unspecified phase) |
0.7703 |
Intermediate Similarity |
NPD4005 |
Discontinued |
0.7692 |
Intermediate Similarity |
NPD1652 |
Phase 2 |
0.7692 |
Intermediate Similarity |
NPD6674 |
Discontinued |
0.7692 |
Intermediate Similarity |
NPD3060 |
Approved |
0.7687 |
Intermediate Similarity |
NPD8651 |
Approved |
0.7667 |
Intermediate Similarity |
NPD37 |
Approved |
0.766 |
Intermediate Similarity |
NPD5588 |
Approved |
0.766 |
Intermediate Similarity |
NPD5960 |
Phase 3 |
0.7632 |
Intermediate Similarity |
NPD4966 |
Approved |
0.7632 |
Intermediate Similarity |
NPD4965 |
Approved |
0.7632 |
Intermediate Similarity |
NPD4967 |
Phase 2 |
0.7632 |
Intermediate Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.7626 |
Intermediate Similarity |
NPD3620 |
Phase 2 |
0.7626 |
Intermediate Similarity |
NPD4060 |
Phase 1 |
0.7626 |
Intermediate Similarity |
NPD3619 |
Clinical (unspecified phase) |
0.7603 |
Intermediate Similarity |
NPD1511 |
Approved |
0.7603 |
Intermediate Similarity |
NPD4357 |
Discontinued |
0.7595 |
Intermediate Similarity |
NPD7054 |
Approved |
0.7594 |
Intermediate Similarity |
NPD422 |
Phase 1 |
0.7586 |
Intermediate Similarity |
NPD2677 |
Approved |
0.7582 |
Intermediate Similarity |
NPD7975 |
Clinical (unspecified phase) |
0.7574 |
Intermediate Similarity |
NPD6917 |
Clinical (unspecified phase) |
0.7571 |
Intermediate Similarity |
NPD5735 |
Approved |
0.7564 |
Intermediate Similarity |
NPD7184 |
Clinical (unspecified phase) |
0.7554 |
Intermediate Similarity |
NPD6233 |
Phase 2 |
0.7554 |
Intermediate Similarity |
NPD1726 |
Clinical (unspecified phase) |
0.7552 |
Intermediate Similarity |
NPD7266 |
Discontinued |
0.7551 |
Intermediate Similarity |
NPD4123 |
Phase 3 |
0.7547 |
Intermediate Similarity |
NPD7074 |
Phase 3 |
0.7547 |
Intermediate Similarity |
NPD7472 |
Approved |
0.754 |
Intermediate Similarity |
NPD3022 |
Approved |
0.754 |
Intermediate Similarity |
NPD3021 |
Approved |
0.7536 |
Intermediate Similarity |
NPD7095 |
Approved |
0.7534 |
Intermediate Similarity |
NPD5058 |
Phase 3 |
0.7534 |
Intermediate Similarity |
NPD7124 |
Phase 2 |
0.7532 |
Intermediate Similarity |
NPD3818 |
Discontinued |
0.7532 |
Intermediate Similarity |
NPD6234 |
Discontinued |
0.7517 |
Intermediate Similarity |
NPD4628 |
Phase 3 |
0.7517 |
Intermediate Similarity |
NPD4109 |
Clinical (unspecified phase) |
0.7517 |
Intermediate Similarity |
NPD4110 |
Phase 3 |
0.7517 |
Intermediate Similarity |
NPD6331 |
Phase 2 |
0.7517 |
Intermediate Similarity |
NPD3892 |
Phase 2 |
0.75 |
Intermediate Similarity |
NPD1940 |
Clinical (unspecified phase) |
0.75 |
Intermediate Similarity |
NPD1512 |
Approved |
0.75 |
Intermediate Similarity |
NPD5261 |
Clinical (unspecified phase) |
0.7484 |
Intermediate Similarity |
NPD5844 |
Phase 1 |
0.7483 |
Intermediate Similarity |
NPD6799 |
Approved |
0.7482 |
Intermediate Similarity |
NPD6798 |
Discontinued |
0.7459 |
Intermediate Similarity |
NPD1242 |
Phase 1 |
0.7447 |
Intermediate Similarity |
NPD5124 |
Phase 1 |
0.7447 |
Intermediate Similarity |
NPD6355 |
Discontinued |
0.7447 |
Intermediate Similarity |
NPD5123 |
Clinical (unspecified phase) |
0.7445 |
Intermediate Similarity |
NPD6584 |
Phase 3 |
0.744 |
Intermediate Similarity |
NPD968 |
Approved |
0.7431 |
Intermediate Similarity |
NPD5763 |
Approved |
0.7431 |
Intermediate Similarity |
NPD5762 |
Approved |
0.7431 |
Intermediate Similarity |
NPD1375 |
Discontinued |
0.7429 |
Intermediate Similarity |
NPD4062 |
Phase 3 |
0.741 |
Intermediate Similarity |
NPD3179 |
Approved |
0.741 |
Intermediate Similarity |
NPD3180 |
Approved |
0.7407 |
Intermediate Similarity |
NPD2231 |
Phase 2 |
0.7407 |
Intermediate Similarity |
NPD7808 |
Phase 3 |
0.7407 |
Intermediate Similarity |
NPD2235 |
Phase 2 |
0.74 |
Intermediate Similarity |
NPD3687 |
Approved |
0.74 |
Intermediate Similarity |
NPD3686 |
Approved |
0.7391 |
Intermediate Similarity |
NPD6797 |
Phase 2 |
0.7386 |
Intermediate Similarity |
NPD7096 |
Clinical (unspecified phase) |
0.7376 |
Intermediate Similarity |
NPD5837 |
Clinical (unspecified phase) |
0.7372 |
Intermediate Similarity |
NPD5494 |
Approved |
0.7365 |
Intermediate Similarity |
NPD6143 |
Clinical (unspecified phase) |
0.7365 |
Intermediate Similarity |
NPD1774 |
Approved |
0.7365 |
Intermediate Similarity |
NPD7212 |
Phase 2 |
0.7365 |
Intermediate Similarity |
NPD7213 |
Phase 3 |
0.7364 |
Intermediate Similarity |
NPD821 |
Approved |
0.7364 |
Intermediate Similarity |
NPD5535 |
Approved |
0.7361 |
Intermediate Similarity |
NPD2161 |
Phase 2 |
0.7361 |
Intermediate Similarity |
NPD2796 |
Approved |
0.7347 |
Intermediate Similarity |
NPD2219 |
Phase 1 |
0.7346 |
Intermediate Similarity |
NPD7251 |
Discontinued |
0.7343 |
Intermediate Similarity |
NPD6111 |
Discontinued |
0.7333 |
Intermediate Similarity |
NPD6980 |
Clinical (unspecified phase) |
0.7329 |
Intermediate Similarity |
NPD5177 |
Phase 3 |
0.7328 |
Intermediate Similarity |
NPD6671 |
Approved |
0.7324 |
Intermediate Similarity |
NPD4340 |
Discontinued |
0.7315 |
Intermediate Similarity |
NPD7447 |
Phase 1 |
0.7312 |
Intermediate Similarity |
NPD7228 |
Approved |
0.731 |
Intermediate Similarity |
NPD1550 |
Clinical (unspecified phase) |
0.731 |
Intermediate Similarity |
NPD1552 |
Clinical (unspecified phase) |
0.7303 |
Intermediate Similarity |
NPD4380 |
Phase 2 |
0.7301 |
Intermediate Similarity |
NPD4338 |
Clinical (unspecified phase) |
0.7292 |
Intermediate Similarity |
NPD6029 |
Clinical (unspecified phase) |
0.7292 |
Intermediate Similarity |
NPD6028 |
Clinical (unspecified phase) |
0.7279 |
Intermediate Similarity |
NPD4535 |
Phase 3 |
0.7279 |
Intermediate Similarity |
NPD1608 |
Approved |
0.7279 |
Intermediate Similarity |
NPD6658 |
Clinical (unspecified phase) |
0.7273 |
Intermediate Similarity |
NPD5773 |
Approved |
0.7273 |
Intermediate Similarity |
NPD6653 |
Approved |
0.7273 |
Intermediate Similarity |
NPD5772 |
Approved |
0.7267 |
Intermediate Similarity |
NPD7526 |
Approved |
0.7267 |
Intermediate Similarity |
NPD52 |
Approved |
0.7267 |
Intermediate Similarity |
NPD7527 |
Clinical (unspecified phase) |
0.7266 |
Intermediate Similarity |
NPD556 |
Approved |
0.726 |
Intermediate Similarity |
NPD2424 |
Discontinued |
0.726 |
Intermediate Similarity |
NPD1549 |
Phase 2 |
0.7254 |
Intermediate Similarity |
NPD2238 |
Phase 2 |
0.7254 |
Intermediate Similarity |
NPD4140 |
Approved |
0.7244 |
Intermediate Similarity |
NPD7075 |
Discontinued |
0.7244 |
Intermediate Similarity |
NPD4381 |
Clinical (unspecified phase) |
0.7234 |
Intermediate Similarity |
NPD5111 |
Phase 2 |
0.7234 |
Intermediate Similarity |
NPD5109 |
Approved |
0.7234 |
Intermediate Similarity |
NPD5110 |
Phase 2 |
0.723 |
Intermediate Similarity |
NPD5241 |
Discontinued |
0.723 |
Intermediate Similarity |
NPD6190 |
Approved |
0.7226 |
Intermediate Similarity |
NPD6583 |
Phase 3 |
0.7226 |
Intermediate Similarity |
NPD2560 |
Approved |
0.7226 |
Intermediate Similarity |
NPD3600 |
Clinical (unspecified phase) |
0.7226 |
Intermediate Similarity |
NPD5402 |
Approved |
0.7226 |
Intermediate Similarity |
NPD6582 |
Phase 2 |
0.7226 |
Intermediate Similarity |
NPD3685 |
Discontinued |
0.7226 |
Intermediate Similarity |
NPD2563 |
Approved |
0.7226 |
Intermediate Similarity |
NPD5327 |
Phase 3 |
0.7219 |
Intermediate Similarity |
NPD5403 |
Approved |
0.7218 |
Intermediate Similarity |
NPD1408 |
Clinical (unspecified phase) |
0.7214 |
Intermediate Similarity |
NPD3537 |
Clinical (unspecified phase) |
0.7208 |
Intermediate Similarity |
NPD6801 |
Discontinued |
0.7203 |
Intermediate Similarity |
NPD230 |
Phase 1 |
0.72 |
Intermediate Similarity |
NPD4378 |
Clinical (unspecified phase) |
0.72 |
Intermediate Similarity |
NPD5401 |
Approved |
0.719 |
Intermediate Similarity |
NPD6599 |
Discontinued |
0.7185 |
Intermediate Similarity |
NPD1778 |
Approved |
0.7183 |
Intermediate Similarity |
NPD2674 |
Phase 3 |
0.7178 |
Intermediate Similarity |
NPD7993 |
Clinical (unspecified phase) |
0.7174 |
Intermediate Similarity |
NPD2922 |
Phase 1 |
0.7172 |
Intermediate Similarity |
NPD2156 |
Approved |
0.7172 |
Intermediate Similarity |
NPD2154 |
Approved |
0.7172 |
Intermediate Similarity |
NPD2155 |
Approved |
0.7172 |
Intermediate Similarity |
NPD7033 |
Discontinued |
0.717 |
Intermediate Similarity |
NPD3787 |
Discontinued |
0.7164 |
Intermediate Similarity |
NPD7534 |
Approved |
0.7164 |
Intermediate Similarity |
NPD1894 |
Discontinued |
0.7164 |
Intermediate Similarity |
NPD1182 |
Approved |
0.7164
|
Intermediate Similarity |
NPD7533 |
Approved |